TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22983495

Group type: EXPERIMENTAL
Intervention: Single-trial EEG using features from ERP components (P1, N1, P2a, P2b)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of features from multiple ERP components
Number of subjects: 0
Study: 19572937

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paracetamol 2 g
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ketoprofen alone
Number of subjects: 114
Study: 17312068

Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization
Number of subjects: 42
Study: 15179650

Group type: EXPERIMENTAL
Intervention: EMPI (1 uniform constant frequency component of 35Hz)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EXPER (experimental form of stimulation with 5 frequency components: 125, 83, 50, 2.5, and 2Hz)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups (EMPI and EXPER)
Number of subjects: 80
Study: 11544790

Group type: EXPERIMENTAL
Intervention: 3 M Multi‐Cure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transbond (APC)
Number of subjects: 20
Study: 9773174

Group type: EXPERIMENTAL
Intervention: Primary care based intervention involving a consultation with an exercise development officer and a personalized 10 week program to increase physical activity levels.
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Primary care based intervention
Number of subjects: 714

Group type: COMPARATOR
Intervention: Control group (sent information on local leisure centres)
Number of subjects: 714
Study: 8148353

Group type: EXPERIMENTAL
Intervention: Rice bran oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 15
Study: 3335991

Group type: EXPERIMENTAL
Intervention: Vivonex
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vital
Number of subjects: 10
Study: 1962595

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg daily
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg daily
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg daily
Number of subjects: 196
Study: 73637

Group type: EXPERIMENTAL
Intervention: Therapeutic end‐to‐side portacaval shunt
Number of subjects: 89

Group type: COMPARATOR
Intervention: No shunt (control group)
Number of subjects: 89
Study: 30730914

Group type: EXPERIMENTAL
Intervention: Women empowerment intervention
Number of subjects: 1463
Study: 26656245

Group type: EXPERIMENTAL
Intervention: Personal intervention (personalized call and mailed appointment reminder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automated intervention (automated call and mailed appointment reminder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no additional intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automated intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25546514

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 500
Study: 23704675

Group type: EXPERIMENTAL
Intervention: Metformin alone (M)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin plus intensive lifestyle program (M+L)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (M+R)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control group (M, M+R, M+L)
Number of subjects: 699
Study: 21422960

Group type: COMPARATOR
Intervention: Placebo (high adherence ≥80%)
Number of subjects: 13444
Study: 19798914

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17909125

Group type: EXPERIMENTAL
Intervention: Combination therapy (fluoxetine + CBT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Fluoxetine therapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 327
Study: 15911154

Group type: EXPERIMENTAL
Intervention: Behavioural medicine rehabilitation (PT+CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behaviour-oriented physiotherapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual control group (CG)
Number of subjects: 0
Study: 11306379

Group type: EXPERIMENTAL
Intervention: MMP-2 excretion
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MMP-9 excretion
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no malignancy)
Number of subjects: 129
Study: 9330417

Group type: EXPERIMENTAL
Intervention: MDI albuterol through a neonatal Aerochamber with non-rebreathing valve
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI albuterol through a neonatal Aerochamber without non-rebreathing valve
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDI albuterol through Babyhaler with one-way inspiratory valve
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI albuterol through Babyhaler without one-way inspiratory valve
Number of subjects: 20
Study: 8173883

Group type: EXPERIMENTAL
Intervention: 22 gauge atraumatic needle
Number of subjects: 107

Group type: COMPARATOR
Intervention: 22 gauge bevel tipped needle
Number of subjects: 107
Study: 3236392

Group type: EXPERIMENTAL
Intervention: MMPI profiles from cluster analysis using average linkage method
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: MMPI profiles from cluster analysis using Ward's hierarchical procedure
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Cluster analysis of other substance abuse populations
Number of subjects: 196
Study: 29345106

Group type: EXPERIMENTAL
Intervention: Nutritional status assessed using the Mini Nutritional Assessment (MNA)
Number of subjects: 3472

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 3472
Study: 29260226

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300

Group type: COMPARATOR
Intervention: No pessary (control)
Number of subjects: 300
Study: 25951953

Group type: EXPERIMENTAL
Intervention: Organizational readiness intervention and integrated collaborative care service delivery intervention
Number of subjects: 0
Study: 22527287

Group type: EXPERIMENTAL
Intervention: Dietary supplement (DS) containing Red yeast rice (RYR), sugar cane‐derived policosanols (SCdP), and artichoke leaf extracts (ALEs)
Number of subjects: 39
Study: 20602869

Group type: EXPERIMENTAL
Intervention: Internet group (n=34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Information-only group (n=31)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 19934666

Group type: EXPERIMENTAL
Intervention: Collaborative care management for depression for young-old patients
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Collaborative care management for depression for old-old patients
Number of subjects: 906
Study: 16968421

Group type: EXPERIMENTAL
Intervention: Epoetin omega
Number of subjects: 132

Group type: COMPARATOR
Intervention: Epoetin alpha
Number of subjects: 132
Study: 15673097

Group type: EXPERIMENTAL
Intervention: Single bout of prolonged cycling in the afternoon (2 h at 60% VO2max starting at 14:00)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Two bouts of cycling (2 h at 60% VO2max starting at 09:00 and 14:00)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Resting trial
Number of subjects: 8
Study: 10385662

Group type: EXPERIMENTAL
Intervention: Prolonged therapy (IFN‐alpha for up to 32 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard therapy (IFN‐alpha for 16 weeks)
Number of subjects: 162
Study: 8708998

Group type: EXPERIMENTAL
Intervention: Financial strain
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Social support withdrawal
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Social undermining increase
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Reduced supportive behaviors
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Increased undermining behaviors
Number of subjects: 815
Study: 1839369

Group type: EXPERIMENTAL
Intervention: Nicorandil (N)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISM)
Number of subjects: 18
Study: 6441537

Group type: EXPERIMENTAL
Intervention: 3 mg piribedil intravenously over a 15 min period
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dopamine receptor blocking agent, haloperidol (pretreated group)
Number of subjects: 10
Study: 29783974

Group type: EXPERIMENTAL
Intervention: Universal prevention (Climate)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Selective prevention (Preventure)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Combined universal and selective prevention (CAP)
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Health education as usual (Control)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Long-term follow-up (5- and 7-years post baseline)
Number of subjects: 2190
Study: 27016084

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel
Number of subjects: 529

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: BPI‐SF worst pain
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: RSCL activity level
Number of subjects: 529
Study: 26581340

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Light exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 9
Study: 23827788

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine
Number of subjects: 494

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine plus amodiaquine
Number of subjects: 494
Study: 20006921

Group type: EXPERIMENTAL
Intervention: Z‐360 120 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Z‐360 240 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Z‐360 (both doses)
Number of subjects: 33
Study: 18283231

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program (29 sessions over 3 months)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control activity (29 sessions over 3 months)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program (among participants who improved balance)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control activity (among participants who improved balance)
Number of subjects: 191
Study: 16172826

Group type: EXPERIMENTAL
Intervention: Blue-dyed food
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular nondyed food (yellow pudding and white skim milk)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular nondyed food
Number of subjects: 20
Study: 14727947

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus a statin (lovastatin, pravastatin, atorvastatin, or simvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus a statin
Number of subjects: 0
Study: 10540365

Group type: EXPERIMENTAL
Intervention: 10% pentastarch
Number of subjects: 32

Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 32
Study: 7812579

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP), n = 14
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group, n = 15
Number of subjects: 29
Study: 2101441

Group type: EXPERIMENTAL
Intervention: Diet plus psychotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 50
Study: 441686

Group type: EXPERIMENTAL
Intervention: High dosage of fluphenazine enanthate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low dosage of fluphenazine enanthate
Number of subjects: 44
Study: 31455589

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills containing drospirenone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 27490418

Group type: EXPERIMENTAL
Intervention: Basiliximab (BAS)/Everolimus (EVR)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (r-ATG)/Everolimus (EVR)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Basiliximab (BAS)/Everolimus (EVR) vs Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (r-ATG)/Everolimus (EVR) vs Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288
Study: 25808940

Group type: EXPERIMENTAL
Intervention: RPV/FTC/TDF
Number of subjects: 476

Group type: COMPARATOR
Intervention: PI + RTV + 2NRTIs
Number of subjects: 476
Study: 23786912

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 21131631

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde pancreatography (ERP) in phase I
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde pancreatography (ERP) in phase II
Number of subjects: 40
Study: 19583605

Group type: EXPERIMENTAL
Intervention: PC-coated circuits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Noncoated circuits (control group)
Number of subjects: 30
Study: 17823681

Group type: EXPERIMENTAL
Intervention: Light curing the adhesive separately (Group PRC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Co-curing the bonding agent with resin composite (Group COC)
Number of subjects: 120
Study: 15183621

Group type: EXPERIMENTAL
Intervention: Cervical cerclage (Shirodkar suture)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 253
Study: 11529355

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment: 250 mg ZDV orally twice a day starting at 38 weeks' gestation until labor, plus ZDV infusion at 2 mg/kg during the first hour of labor and then 1 mg/kg/h until delivery.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo treatment: identical capsule during pregnancy and normal saline infusion during labor until delivery.
Number of subjects: 182
Study: 9763051

Group type: EXPERIMENTAL
Intervention: Early postnatal check-up (1 week after discharge)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Traditional postnatal check-up (6 weeks after birth)
Number of subjects: 683
Study: 8853219

Group type: EXPERIMENTAL
Intervention: Methylphenidate preceded by haloperidol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methylphenidate preceded by placebo and then haloperidol
Number of subjects: 10
Study: 2145656

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (0.1 mumol)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (0.15M NaCl)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms, 0.6 mumol)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, 0.1 mumol)
Number of subjects: 7
Study: 7461330

Group type: EXPERIMENTAL
Intervention: Rapid 'empiric' digitalization (group I)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Slow 'empiric' digitalization (group II)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: 'Rational' digitalization (group III)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Initial 'empiric' dosage followed by 'rational' maintenance (group IV)
Number of subjects: 454
Study: 31888691

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Fear Reduction Efficacy Evaluation [FREE]) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control group receiving diabetes self-management education (DSME) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (FREE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control group (DSME)
Number of subjects: 50
Study: 28382697

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 26356708

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU once daily
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) 5000 IU twice daily
Number of subjects: 3746
Study: 23325376

Group type: EXPERIMENTAL
Intervention: Healthy Choices
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study: 20435259

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BAP)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Bypass Surgery (BSX)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Bypass Surgery (BSX) with vein
Number of subjects: 452

Group type: COMPARATOR
Intervention: Bypass Surgery (BSX) after failed BAP
Number of subjects: 452
Study: 17600649

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Treatment arm guess
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Bupropion efficacy
Number of subjects: 498
Study: 16636358

Group type: EXPERIMENTAL
Intervention: Sucrose (2 mL)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 83
Study: 12748500

Group type: EXPERIMENTAL
Intervention: Oral estradiol replacement
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no estradiol replacement)
Number of subjects: 43
Study: 10978944

Group type: EXPERIMENTAL
Intervention: 4 mg loperamide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 8 mg loperamide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 12 mg loperamide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lactase tablets
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 8595970

Group type: EXPERIMENTAL
Intervention: timolol 0.5% twice a day (b.i.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: timolol 0.5% b.i.d. (6 months) alternated with 0.1% dipivefrin b.i.d. (2 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: dipivefrin
Number of subjects: 100
Study: 1720485

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 51
Study: 7034473

Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg IV followed by a total daily dose of 200 mg/day
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 31818160

Group type: EXPERIMENTAL
Intervention: Liquid-isolating maneuver (LIM)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Lever-elevating maneuver (LEM)
Number of subjects: 174
Study: 28673363

Group type: EXPERIMENTAL
Intervention: RYR-olive extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Number of subjects: 50
Study: 25308877

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age‐ and sex‐matched controls)
Number of subjects: 30
Study: 23298376

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day for 14 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21777097

Group type: EXPERIMENTAL
Intervention: Vivasens
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BisBlock
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clearfil SE + Nd:YAG laser
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study: 19302635

Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg.kg(‐1) bolus followed by 250 microg.kg(‐1)min(‐1) infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no esmolol)
Number of subjects: 60
Study: 17515571

Group type: EXPERIMENTAL
Intervention: Radiotherapy only or nonalkylating chemotherapy (ABVD, EBVP)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Chemotherapy containing alkylating agents (MOPP, ABV, BEACOPP)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Nonalkylating chemotherapy
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Alkylating chemotherapy
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Higher doses of alkylating chemotherapy
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Age more than 50 years and stage II disease
Number of subjects: 355
Study: 15504375

Group type: EXPERIMENTAL
Intervention: 35 microg ethinyl estradiol (21)/180 microg norgestimate (7)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol (21)/150 microg desogestrel (21)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol (21)/100 microg levonorgestrel (21)
Number of subjects: 36
Study: 11472042

Group type: EXPERIMENTAL
Intervention: Invasive treatment (open surgical or endovascular procedures)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 264
Study: 9492829

Group type: EXPERIMENTAL
Intervention: 5'-deoxy-5-fluorouridine (5'-DFUR) administration at a dose of 1,200 mg/body for 7 days
Number of subjects: 0
Study: 8049831

Group type: EXPERIMENTAL
Intervention: Active patch delivering 11 mg of nicotine over 24 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study: 2839529

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17